CO7 Patient reported outcome measure for giant cell arteritis: cross-sectional validation study
(2022)
Journal Article
Ndosi, M., Almeida, C., Dawson, J., Dures, E., Greenwood, R., Guly, C., …Robson, J. (2022). CO7 Patient reported outcome measure for giant cell arteritis: cross-sectional validation study. Value in Health, 25(7, Supplement), Page S305. https://doi.org/10.1016/j.jval.2022.04.105
Browse
POS0003 Development and validation of a disease specific patient reported outcome for giant cell arteritis (2022)
Conference Proceeding
Robson, J., Almeida, C., Dawson, J., Dures, E., Greenwood, R., Guly, C., …Ndosi, M. (2022). POS0003 Development and validation of a disease specific patient reported outcome for giant cell arteritis. . https://doi.org/10.1136/annrheumdis-2022-eular.1769Background Giant cell arteritis (GCA) is caused by inflammation of the blood vessels of the head and neck; patients can present with cranial, ocular or large vessel vasculitis involvement. Treatment is with glucocorticoids, steroid sparing agents a... Read More about POS0003 Development and validation of a disease specific patient reported outcome for giant cell arteritis.
P301 Patient reported outcome measure for giant cell arteritis: Clinical testing (2022)
Journal Article
Almeida, C., Guly, C., Mackie, S., Bromhead, A., Stern, S., Dures, E., …Robson, J. C. (2022). P301 Patient reported outcome measure for giant cell arteritis: Clinical testing. Rheumatology, 61(Supplement_1), Article keac133.300. https://doi.org/10.1093/rheumatology/keac133.300Background/Aims Giant cell arteritis (GCA) presents in people over 50, with headaches, visual involvement and large vessel vasculitis. A 30-item GCA-specific patient reported outcome measure (GCA PRO) was developed and tested in a clinical setting t... Read More about P301 Patient reported outcome measure for giant cell arteritis: Clinical testing.
OA23 Patient-reported outcome measure for giant cell arteritis: Cross-sectional validation study (2022)
Journal Article
Ndosi, M., Almeida, C., Dawson, J., Dures, E., Greenwood, R., Guly, C., …Robson, J. C. (2022). OA23 Patient-reported outcome measure for giant cell arteritis: Cross-sectional validation study. Rheumatology, 61(Supplement_1), https://doi.org/10.1093/rheumatology/keac132.023
Development and validation of a patient reported outcome measure for giant cell arteritis (2021)
Presentation / Conference
Ndosi, M., Almeida, C., Dawson, J., Dures, E., Greenwood, R., Guly, C., …Robson, J. (2021, November). Development and validation of a patient reported outcome measure for giant cell arteritis. Poster presented at ACR Convergence 2021, Online
Patient perceptions of physical activity after a diagnosis of giant cell arteritis: Analysis of multinational qualitative data (2021)
Journal Article
Austin, K., Dures, E., Almeida, C., Cramp, F., Guly, C. M., Hill, C. L., …Robson, J. C. (2022). Patient perceptions of physical activity after a diagnosis of giant cell arteritis: Analysis of multinational qualitative data. Arthritis Care and Research, 74(1), 99-106. https://doi.org/10.1002/acr.24800Objective: To explore patient perceptions of physical activity in giant cell arteritis (GCA). Methods: This was a multinational qualitative study, analyzing interview data collected from participants from the UK (n=25) and Australia (n=11) with a def... Read More about Patient perceptions of physical activity after a diagnosis of giant cell arteritis: Analysis of multinational qualitative data.
Patient perceptions of health-related quality of life in giant cell arteritis: International development of a disease-specific patient-reported outcome measure (2021)
Journal Article
Robson, J. C., Almeida, C., Dawson, J., Bromhead, A., Dures, E., Guly, C., …Hill, C. (2021). Patient perceptions of health-related quality of life in giant cell arteritis: International development of a disease-specific patient-reported outcome measure. Rheumatology, 60(10), 4671-4680. https://doi.org/10.1093/rheumatology/keab076Objectives: GCA is a large vessel vasculitis (LVV) presenting with headache, jaw claudication, musculoskeletal and visual involvement. Current treatment is glucocorticoids and anti-IL-6 tocilizumab in refractory disease. The objective of this study w... Read More about Patient perceptions of health-related quality of life in giant cell arteritis: International development of a disease-specific patient-reported outcome measure.
Patient reported outcomes in large vessel vasculitides (2021)
Journal Article
Robson, J., Mackie, S., & Hill, C. (2021). Patient reported outcomes in large vessel vasculitides. Current Rheumatology Reports, 23(2), Article 7. https://doi.org/10.1007/s11926-020-00979-4Purpose of Review: The goal of this paper is to review current and future uses of patient-reported outcomes in large vessel vasculitis. The large vessel vasculitides comprise Giant Cell Arteritis and Takayasu arteritis; both are types of systemic vas... Read More about Patient reported outcomes in large vessel vasculitides.
Advancing stiffness measurement in rheumatic disease: Report from the stiffness special interest group at OMERACT 2018 (2019)
Journal Article
Craig, E. T., Orbai, A., Mackie, S., Bartlett, S. J., Bingham, C. O., Goodman, S., …Halls, S. (2019). Advancing stiffness measurement in rheumatic disease: Report from the stiffness special interest group at OMERACT 2018. Journal of Rheumatology, 46(10), 1374-1378. https://doi.org/10.3899/jrheum.181074Objective. To improve measurement of stiffness in rheumatic disease. Methods. Data presented included (1) 2 qualitative projects, (2) the rheumatoid arthritis (RA) stiffness patient-reported outcome measure (RAST), and (3) 3 items assessing stiffn... Read More about Advancing stiffness measurement in rheumatic disease: Report from the stiffness special interest group at OMERACT 2018.
Update on outcome measure development in large-vessel vasculitis: Report from OMERACT 2018 (2019)
Journal Article
Merkel, P. A., Direskeneli, H., Tugwell, P., Tómasson, G., Shea, B., Milman, N., …Hill, C. (2019). Update on outcome measure development in large-vessel vasculitis: Report from OMERACT 2018. Journal of Rheumatology, 46(9), 1198-1201. https://doi.org/10.3899/jrheum.181072OBJECTIVE: The OMERACT Vasculitis Working Group seeks to develop validated outcome measures for use in trials for large-vessel vasculitis (LVV). METHODS: An international Delphi exercise conducted among investigators identified items considered... Read More about Update on outcome measure development in large-vessel vasculitis: Report from OMERACT 2018.